13th Edition of International Conference on Neurology and Brain Disorders
October 19-21, 2026
Neurogenetics
The field of neurogenetics is dedicated to understanding the role of genetics in the development and progression of neurological disorders. Researchers are uncovering how mutations in specific genes lead to a wide range of conditions, from rare inherited diseases to more common neurological disorders like multiple sclerosis and Parkinson’s disease. The use of advanced technologies, such as genome-wide association studies (GWAS), is helping to identify new genetic variants associated with neurological diseases, offering insights into their underlying causes. Furthermore, the advent of gene therapy and genome editing techniques is providing new hope for treating genetic neurological conditions by correcting or replacing faulty genes. The study of epigenetics also plays a vital role in understanding how environmental factors influence genetic expression in the brain.
Ken Ware
NeuroPhysics Therapy Institute and Research Centre, Australia
Yong Xiao Wang
Albany Medical College, United States
Joe Sam Robinson
Mercer University, United States
Daniel Curry
Texas Children’s Hospital, United States
Steven Benvenisti
Davis, Saperstein Salomon, PC, United States
Andrzej Stanislaw Cieplak
Independent researcher, United States
Younok Dumortier Shin
OnusBio, United StatesSubmit your abstract Today
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States